A carregar...
Myeloproliferative neoplasms: From JAK2 mutations discovery to JAK2 inhibitor therapies
Most BCR-ABL1-negative myeloproliferative neoplasms (MPN) carry an activating JAK2 mutation. Approximately 96% of patients with polycythemia vera (PV) harbors the V617F mutation in JAK2 exon 14, whereas the minority of JAK2 (V617F)-negative subjects shows several mutations in exon 12. Other mutation...
Na minha lista:
| Main Authors: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Impact Journals LLC
2011
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3248205/ https://ncbi.nlm.nih.gov/pubmed/21646683 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|